Figure 3. Prespecified Subgroup Analysis of Patients Who Died or Experienced Rehospitalization for Heart Failure by Type 2 Diabetes Status.
HR indicates hazard ratio. The median duration of follow-up was 179 days (interquartile range, 157–182 days) in the liraglutide group and 178 days (interquartile range, 150–183 days) in the placebo group.